Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.
1. A biodegradable implant adapted for intraocular use, the implant comprising:
(a) about 40 weight % brimonidine free base;
(b) about 10 weight % brimonidine tartrate;
(c) about 20 weight % first ester end-capped poly (D,L-lactide) polymer having an inherent viscosity of about 0.3 dL/g;
(d) about 20 weight % second ester end-capped poly (D,L-lactide) polymer; and
(e) about 10 weight % acid end-capped poly (D,L-lactide) polymer having an inherent viscosity of about 0.2 dL/g; and
wherein the implant exhibits a substantially linear release of brimonidine over a period of time from about 20 days to about 50 days.
2. A method for treating glaucoma comprising the step of intraocular administration of a biodegradable intraocular implant comprising:
(a) about 40 weight % brimonidine free base;
(b) about 10 weight % brimonidine tartrate;
(c) about 20 weight % first ester end-capped poly (D,L-lactide) polymer having an inherent viscosity of about 0.3 dL/g;
(d) about 20 weight % second ester end-capped poly (D,L-lactide) polymer; and
(e) about 10 weight % acid end-capped poly (D,L-lactide) polymer having an inherent viscosity of about 0.2 dL/g; and
wherein the implant exhibits a substantially linear release of brimonidine over a period of time from about 20 days to about 50 days.